ATNM-400 Shows Superior Tumor Control and Durable Efficacy in Resistant Prostate Cancer Models
New Preclinical Data Highlights Major Step Forward for Patients With Limited Treatment Options
Actinium Pharmaceuticals' latest data release puts the spotlight on ATNM-400—a first-in-class radiotherapy—showing not just potent anti-tumor activity but extended survival even in challenging, treatment-resistant prostate cancer settings. The findings, presented at the 32nd Annual Prostate Cancer Foundation Scientific Retreat, set a new bar for how the field may tackle therapy-resistant and advanced cases.
Key Efficacy Metrics: ATNM-400 Outperforms Standard Therapies
Unlike existing therapies that depend on targeting PSMA, ATNM-400 goes after a novel, non-PSMA antigen that stays present even after other treatments fail. The numbers stand out:
| Therapy | Tumor Control Duration | Complete Tumor Regression | Survival Benefit |
|---|---|---|---|
| ATNM-400 (monotherapy) | Up to 100 days | Robust in post-enzalutamide setting | 5x vs enzalutamide alone |
| Enzalutamide (Xtandi®) | Approx. 20 days | No durable disease control | - |
| ATNM-400 + Enzalutamide | Significantly extended | 40% | Markedly prolonged |
| 177Lu-PSMA-617 (Pluvicto®) | Lower, limited by resistance | - | 2x shorter than ATNM-400 |
In head-to-head preclinical studies, ATNM-400’s efficacy extended far beyond current therapies—achieving five times the tumor control and complete regression in 40% of animals when combined with enzalutamide.
Mechanism Targets Treatment-Resistant Disease—Filling a Critical Gap
Most notably, ATNM-400 targets a non-PSMA antigen linked to both prostate cancer progression and resistance to standard-of-care agents. That means ATNM-400 can maintain its impact in patients whose tumors don’t express PSMA—a key hurdle for therapies like Pluvicto®, which cannot benefit 25%-30% of mCRPC (metastatic castration-resistant prostate cancer) patients lacking PSMA or with mixed-expression disease. As many as 60% of patients harbor at least one PSMA-negative lesion.
The robust data shows ATNM-400 working effectively even after tumors progress on enzalutamide and 177Lu-PSMA-617, supporting the promise for hard-to-treat populations. In the press release, Actinium's CEO highlighted, "ATNM-400 combines the precision of antibody targeting with the potency of Ac-225 alpha particles, through a biologically distinct, PSMA-independent mechanism."
Expanding the Playbook: Synergy With AR Pathway Inhibitors and Beyond
The story doesn't end with prostate cancer. ATNM-400, paired with enzalutamide, yielded complete tumor eradication in 40% of tested animals—a demonstration of strong synergy with AR pathway inhibition. Notably, data being presented at additional conferences indicates promise for non-small cell lung cancer, as well—specifically, overcoming resistance to therapies like osimertinib (TAGRISSO®).
ATNM-400 is being positioned not only for monotherapy use but as a component of future combination or sequential regimens—broadening its relevance across different lines of cancer care.
What’s Next: The Outlook for ATNM-400 in Oncology
With prostate cancer and non-small cell lung cancer accounting for roughly 500,000 new cases annually in the U.S., the potential clinical and commercial impact of a versatile agent like ATNM-400 is significant. While these are preclinical results, the consistency across resistant disease models, along with its multi-indication strategy, signals a real opportunity for a shift in standard-of-care in advanced prostate cancer.
Bottom Line: A Promising Candidate to Watch as Resistance Remains an Unmet Need
The headline takeaway is clear—ATNM-400 shows potential to reshape how clinicians approach resistant prostate and potentially lung cancer. For investors and clinicians alike, tracking further clinical progress could provide early insight into a therapy aiming to overcome one of cancer's toughest barriers: drug resistance.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI